Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged ≥ 65 Years in the US during the 2019–20 Influenza Season—A Retrospective Cohort Analysis

Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged ≥ 65 Years in the US during the 2019–20 Influenza Season—A Retrospective Cohort Analysis

The burden of influenza is disproportionally higher among older adults. We evaluated the relative vaccine effectiveness (rVE) of adjuvanted trivalent (aIIV3) compared to high-dose trivalent influenza vaccine (HD-IIV3e) against influenza and cardio-respiratory disease (CRD)-related hospitalizations/E...

Full description

Bibliographic Details
Main Authors: Myron J. Levin, Victoria Divino, Drishti Shah, Mitch DeKoven, Joaquin Mould-Quevedo, Stephen I. Pelton, Maarten J. Postma
Format: Article
Language:English
Published: MDPI AG 2021-10-01
Series:Vaccines
Subjects:
influenza
older adults
adjuvanted influenza vaccine
relative vaccine effectiveness
retrospective studies
economic outcomes
Online Access:https://www.mdpi.com/2076-393X/9/10/1146

Internet

https://www.mdpi.com/2076-393X/9/10/1146

Similar Items